|
US7176232B2
(en)
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
|
US7232818B2
(en)
*
|
2004-04-15 |
2007-06-19 |
Proteolix, Inc. |
Compounds for enzyme inhibition
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
JP5616569B2
(ja)
|
2004-04-15 |
2014-10-29 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
酵素阻害のための化合物
|
|
US20050256324A1
(en)
*
|
2004-05-10 |
2005-11-17 |
Proteolix, Inc. |
Synthesis of amino acid keto-epoxides
|
|
BRPI0510802A
(pt)
|
2004-05-10 |
2007-11-06 |
Proteolix Inc |
compostos para inibição de enzima
|
|
MX2007006526A
(es)
|
2004-12-03 |
2007-09-19 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para tratamiento de enfermedades neoplasicas.
|
|
CN101180071A
(zh)
*
|
2004-12-07 |
2008-05-14 |
普罗特奥里克斯公司 |
抑制蛋白酶体的组合物
|
|
JP5436860B2
(ja)
|
2005-11-09 |
2014-03-05 |
オニキス セラピューティクス， インク． |
酵素阻害のための化合物
|
|
NZ573759A
(en)
|
2006-06-19 |
2012-03-30 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
EP2040694A2
(en)
*
|
2006-07-14 |
2009-04-01 |
VIB vzw |
Use of ppar-alpha agonists to treat skeletal muscle wasting disorders
|
|
US7642369B2
(en)
*
|
2006-09-12 |
2010-01-05 |
University Of Kentucky Research Foundation |
Epoxyketone-based immunoproteasome inhibitors
|
|
EA018973B1
(ru)
|
2007-10-04 |
2013-12-30 |
Оникс Терапьютикс, Инк. |
Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
|
|
AU2016231532B2
(en)
*
|
2007-10-04 |
2018-05-10 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
AU2013203566B2
(en)
*
|
2007-10-04 |
2016-10-13 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
|
EP2088205A1
(en)
|
2008-02-11 |
2009-08-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
AU2009246467A1
(en)
*
|
2008-05-12 |
2009-11-19 |
Nereus Pharmaceuticals, Inc. |
Salinosporamide derivatives as proteasome inhibitors
|
|
BRPI0919668A2
(pt)
|
2008-10-21 |
2018-05-29 |
Onyx Therapeutics, Inc. |
terapia de combinação com epóxi-cetonas de peptídeo
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
US20110009332A1
(en)
*
|
2009-07-09 |
2011-01-13 |
Southwest Research Institute |
Therapeutic Treatment Of Wounds
|
|
GB0914883D0
(en)
|
2009-08-26 |
2009-09-30 |
Univ Belfast |
Compound
|
|
EP2498793B1
(en)
|
2009-11-13 |
2019-07-10 |
Onyx Therapeutics, Inc. |
Oprozomib for use in metastasis suppression
|
|
PH12012501719A1
(en)
|
2010-03-01 |
2012-11-12 |
Onyx Therapeutics Inc |
Compounds for immunoproteasome inhibition
|
|
US8697646B2
(en)
|
2010-04-07 |
2014-04-15 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
US9126997B1
(en)
|
2010-09-07 |
2015-09-08 |
Northwestern University |
Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
|
|
US9272014B2
(en)
|
2011-03-29 |
2016-03-01 |
Texas Tech University System |
Galectin-3C combination therapy for human cancer
|
|
WO2013009923A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Creighton University |
Methods of promoting neuron growth
|
|
CA2855356A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
|
CA2855368A1
(en)
|
2011-11-11 |
2013-05-16 |
Millennium Pharmaceuticals, Inc. |
Biomarkers of response to proteasome inhibitors
|
|
CA2862492A1
(en)
|
2012-01-24 |
2013-08-01 |
Millennium Pharmaceuticals, Inc. |
Methods of treatment of cancer
|
|
EP4083075A1
(en)
|
2012-02-15 |
2022-11-02 |
CyDex Pharmaceuticals, Inc. |
Manufacturing process for cyclodextrin derivatives
|
|
CN104411334A
(zh)
|
2012-05-08 |
2015-03-11 |
欧尼斯治疗公司 |
用于配制肽蛋白酶体抑制剂的环糊精络合法
|
|
US9309283B2
(en)
|
2012-07-09 |
2016-04-12 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
JP2015524411A
(ja)
|
2012-07-18 |
2015-08-24 |
オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
|
|
CA2881986A1
(en)
*
|
2012-08-21 |
2014-02-27 |
Fluorinov Pharma Inc. |
Fluorinated epoxyketone-based tetrapeptide compounds and uses thereof as proteasome inhibitors
|
|
HK1213585A1
(zh)
|
2012-10-22 |
2016-07-08 |
Cydex Pharmaceuticals, Inc. |
烷基化环糊精组合物及其制备和使用方法
|
|
JP6279065B2
(ja)
|
2013-03-13 |
2018-02-14 |
サノフイ |
抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
|
|
EA030957B1
(ru)
|
2013-03-14 |
2018-10-31 |
Оникс Терапьютикс, Инк. |
Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
|
|
AR095426A1
(es)
|
2013-03-14 |
2015-10-14 |
Onyx Therapeutics Inc |
Inhibidores tripeptídicos de la epoxicetona proteasa
|
|
US20160166632A1
(en)
|
2013-07-19 |
2016-06-16 |
Onyx Therapeutics, Inc. |
Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
|
|
CN103360348B
(zh)
*
|
2013-07-25 |
2015-06-24 |
苏州鹏旭医药科技有限公司 |
一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
|
|
CA2920220A1
(en)
*
|
2013-09-06 |
2015-03-12 |
Sandoz Ag |
Synthesis of peptide epoxy ketones
|
|
CN105517998A
(zh)
*
|
2013-09-06 |
2016-04-20 |
桑多斯股份公司 |
通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
|
|
WO2015121769A1
(en)
|
2014-02-13 |
2015-08-20 |
Ranbaxy Laboratories Limited |
Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
|
|
CN103864889B
(zh)
*
|
2014-04-04 |
2017-01-11 |
重庆泰濠制药有限公司 |
环氧酮化合物、其制备方法及卡非佐米的制备方法
|
|
PT3183295T
(pt)
|
2014-08-22 |
2023-11-03 |
Cydex Pharmaceuticals Inc |
Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
|
|
US10329325B2
(en)
|
2014-09-24 |
2019-06-25 |
Biophore India Pharmaceuticals Pvt. Ltd |
Process for the preparation of (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxo-pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
|
|
WO2016069479A1
(en)
|
2014-10-27 |
2016-05-06 |
Apicore Us Llc |
Methods of making carfilzomib and intermediates thereof
|
|
CN104402973A
(zh)
*
|
2014-11-24 |
2015-03-11 |
重庆泰濠制药有限公司 |
一种卡非佐米无定型晶的制备方法
|
|
US10253066B2
(en)
|
2014-12-02 |
2019-04-09 |
Fresenius Kabi Oncology Limited |
Process for purification of Carfilzomib
|
|
WO2016108204A1
(en)
|
2014-12-31 |
2016-07-07 |
Dr. Reddy's Laboratories Limited |
Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib
|
|
US10544189B2
(en)
|
2015-04-22 |
2020-01-28 |
Msn Laboratories Private Limited |
Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
|
|
EP3297678B1
(en)
|
2015-05-21 |
2021-07-07 |
Laurus Labs Limited |
An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
|
|
CN106317188A
(zh)
*
|
2015-06-18 |
2017-01-11 |
重庆医药工业研究院有限责任公司 |
一种制备卡非佐米无定型物的方法
|
|
WO2017032487A1
(en)
|
2015-08-27 |
2017-03-02 |
Technische Universität München |
Proteasome inhibitor comprising a signal-emitting moiety
|
|
WO2017098532A1
(en)
|
2015-12-11 |
2017-06-15 |
Mylan Laboratories Limited |
Crystalline and amorphous forms of carfilzomib
|
|
TWI636052B
(zh)
*
|
2015-12-31 |
2018-09-21 |
中化合成生技股份有限公司 |
無定形卡非佐米(i)的製備方法
|
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
|
TWI759301B
(zh)
|
2016-05-24 |
2022-04-01 |
美商安美基公司 |
聚乙二醇化卡非佐米化合物
|
|
WO2018024645A1
(en)
|
2016-08-02 |
2018-02-08 |
Synthon B.V. |
Process for making carfilzomib
|
|
SI3494108T1
(sl)
|
2016-08-05 |
2021-02-26 |
Amgen Inc., |
Sinteza spojine (S)-2-amino-4-metil-1-((R)-2-metiloksiran-2-il)-pentan-1-on in njenih farmacevtsko sprejemljivih soli
|
|
US11078231B2
(en)
|
2016-09-14 |
2021-08-03 |
Fresenius Kabi Oncology Ltd |
Process for purification of carfilzomib intermediate
|
|
EP3512602B1
(en)
|
2016-09-16 |
2024-03-27 |
HSF Pharmaceuticals |
Inhibitors of heat shock factors (hsf) and uses thereof
|
|
EP3330260A1
(en)
|
2016-12-01 |
2018-06-06 |
Enantia, S.L. |
Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
|
|
JP2020533382A
(ja)
|
2017-09-14 |
2020-11-19 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
癌の組合せ治療
|
|
IL274099B2
(en)
|
2017-11-16 |
2026-03-01 |
Amgen Inc |
Stable formulations of PEG-modified carfilzomib formulations
|
|
CN117051096A
(zh)
*
|
2017-12-08 |
2023-11-14 |
神经Gx有限责任公司 |
用于阿尔茨海默病的同步化细胞周期基因表达测试及相关治疗方法
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
US10689416B2
(en)
|
2017-12-30 |
2020-06-23 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
WO2019133988A1
(en)
|
2017-12-30 |
2019-07-04 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
IL279526B2
(en)
*
|
2018-06-22 |
2026-05-01 |
Ucl Business Ltd |
Compounds for the treatment of alpha-1 antitrypsin-mediated diseases
|
|
WO2021072212A1
(en)
*
|
2019-10-11 |
2021-04-15 |
Mayo Foundation For Medical Education And Research |
Proteasome inhibitors
|
|
EP4139289A1
(en)
*
|
2020-04-21 |
2023-03-01 |
University of Rochester |
Inhibitors of human epididymus protein 4
|
|
US20250302954A1
(en)
|
2022-05-11 |
2025-10-02 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
US20250295771A1
(en)
|
2022-05-11 |
2025-09-25 |
Celgene Corporation |
Methods and uses related to t cell therapy and production of same
|
|
WO2024069240A2
(en)
|
2022-09-29 |
2024-04-04 |
Takeda Pharmaceutical Company Limited |
Cd38-binding fusion protein combination therapy
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
CN116768972A
(zh)
*
|
2023-06-25 |
2023-09-19 |
重庆药友制药有限责任公司 |
一种卡非佐米中间体的制备方法
|
|
WO2025035020A2
(en)
|
2023-08-09 |
2025-02-13 |
Amgen Inc. |
Methods of using carfilzomib
|
|
EP4685151A1
(en)
|
2024-07-24 |
2026-01-28 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Proteasome inhibitor
|